Syngenta Considers More Takeovers for Seeds, Bio-Control

Syngenta AG (SYNN), the world’s largest maker of crop chemicals, said it will continue to pursue takeovers after agreeing to buy Belgian hybrid-rice maker Devgen last month.

“This is an example where in one quarter we can take three quarters of a billion dollars off the balance sheet without a blink,” Chief Financial Officer John Ramsay said in an interview. “M&A continues to be a major part of our strategy.”

The Swiss company is seeking to overcome resistance to chemical-based pesticides, its largest business, by buying up smaller makers of biological alternatives as well as genetically modified traits to boost revenue to $25 billion by 2020 from $13.3 billion. Syngenta last month agreed to buy Devgen for 403 million euros ($526 million) and biological controls company Pasteuria Bioscience for $113 million.

Third-quarter sales rose 1.3 percent from a year earlier to $2.7 billion, Basel-based Syngenta said in a statement today. That compared with the $2.76 billion average estimate of analysts in a Bloomberg survey. Competitor Monsanto Co. (MON) reported sales on Oct. 3 that missed analyst estimates.

Syngenta shares rose 1 percent to 346.9 Swiss francs as of 10:08 a.m. in Zurich.

There are “very few, perhaps one or two” viable takeover targets left on the market, Ramsay said, as Syngenta battles rivals to capture the most innovative bug-fighting technologies.

BASF SE (BAS) and Bayer AG (BAYN) have pumped up their biological crop- chemicals units. BASF agreed to buy Becker Underwood Inc. for $1.02 billion in September and Bayer said in July that it would buy Agraquest Inc. for $425 million.

Drought restrained Syngenta’s fungicide sales in the U.S. in the third quarter and a delayed monsoon caused a shortfall in crop-chemical sales in India and Japan even as sales rose 18 percent in Latin America amid higher soybean prices.

To contact the reporter on this story: Patrick Winters in Zurich at pwinters3@bloomberg.net

To contact the editor responsible for this story: Benedikt Kammel at bkammel@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.